Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 6, 2012, Pages 956-966

  Arrichiello, C ^a   Aloj, L ^a   Mormile, M ^a   D'Ambrosio, L ^a   Frigeri, F ^a   Caraco C ^a   Arcamone, M ^a   De Martinis, F ^a   Pinto, A ^a   Lastoria, S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bremsstrahlung imaging; Dosimetry; Ibritumomab tiuxetan; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; INDIUM 111; UNCLASSIFIED DRUG; YTTRIUM 90; YTTRIUM 90 IBRITUMOMAB TIUXETAN;

ARTICLE; BLOOD SAMPLING; BONE MARROW; BREMS RADIATION; CLINICAL ARTICLE; DOSIMETRY; ECHO PLANAR IMAGING; FOLLICULAR LYMPHOMA; HUMAN; ISOTOPE LABELING; NONHODGKIN LYMPHOMA; PREMEDICATION; RADIOACTIVITY; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; FEASIBILITY STUDIES; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE;

EID: 84862666325     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2040-5     Document Type: Article

References (31)

1. AV Rao G Akabani DA Rizzieri 2005 Radioimmunotherapy for non-Hodgkin's lymphoma Clin Med Res 3 157 165 16160070 10.3121/cmr.3.3.157 1:CAS:528:DC%2BD2MXhtFeisLjI
2. PC Chinn JE Leonard J Rosenberg N Hanna DR Anderson 1999 Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma Int J Oncol 15 1017 1025 10536187 1:CAS:528: DyaK1MXnsFGisbo%3D
3. ME Juweid 2002 Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice J Nucl Med 43 1507 1529 12411555 1:CAS:528:DC%2BD38XptV2mtL4%3D
4. SJ Knox ML Goris K Trisler R Negrin T Davis TM Liles, et al. 1996 Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Clin Cancer Res 2 457 470 9816191 1:CAS:528:DyaK28XitVymu78%3D
5. F Morschhauser J Radford A Van Hoof U Vitolo P Soubeyran H Tilly, et al. 2008 Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 5156 5164 18854568 10.1200/JCO.2008.17.2015 1:CAS:528:DC%2BD1cXhsVyqsrnE
6. TE Witzig LI Gordon F Cabanillas MS Czuczman C Emmanouilides R Joyce, et al. 2002 Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2453 2463 12011122 10.1200/JCO.2002.11.076 1:CAS:528: DC%2BD38XksFakur0%3D
7. TE Witzig A Molina LI Gordon C Emmanouilides RJ Schilder IW Flinn, et al. 2007 Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan Cancer 109 1804 1810 17380530 10.1002/cncr.22617 1:CAS:528:DC%2BD2sXlsF2nurw%3D
8. AJ Grillo-Lopez 2002 Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma Expert Rev Anticancer Ther 2 485 493 12382517 10.1586/14737140.2.5.485 1:CAS:528:DC%2BD38XotlGnsbg%3D
9. T Illidge F Morschhauser 2011 Radioimmunotherapy in follicular lymphoma Best Pract Res Clin Haematol. 24 279 293 21658624 10.1016/j.beha.2011.03.005
10. F Morschhauser M Dreyling A Rohatiner F Hagemeister A Bischof Delaloye 2009 Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence Oncologist 14 Suppl 2 17 29 19819921 10.1634/theoncologist.2009-S2-17 1:CAS:528: DC%2BD1MXhsVyhsrfK
11. TE Witzig CA White GA Wiseman LI Gordon C Emmanouilides A Raubitschek, et al. 1999 Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma J Clin Oncol 17 3793 3803 10577851 1:CAS:528:DC%2BD3cXhsVCiug%3D%3D
12. L Devizzi A Guidetti C Tarella M Magni P Matteucci E Seregni, et al. 2008 High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation J Clin Oncol 26 5175 5182 18854569 10.1200/JCO.2008.16.8294 1:CAS:528:DC%2BD1cXhsVyqsrnF
13. SA Jacobs 2007 Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects Biologics 1 215 227 19707332 1:CAS:528:DC%2BD1cXjt1Wmurw%3D
14. PS Conti C White P Pieslor A Molina J Aussie P Foster 2005 The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry J Nucl Med 46 1812 1818 16269594 1:CAS:528:DC%2BD28XitVGltL8%3D
15. GA Wiseman CA White M Stabin WL Dunn W Erwin M Dahlbom, et al. 2000 Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Eur J Nucl Med. 27 766 777 10952488 10.1007/s002590000276 1:CAS:528:DC%2BD3cXktVOjsL8%3D
16. GA Wiseman E Kornmehl B Leigh WD Erwin DA Podoloff S Spies, et al. 2003 Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials J Nucl Med 44 465 474 12621016 1:CAS:528:DC%2BD3sXislKnurw%3D
17. S Shen GL DeNardo A Yuan DA DeNardo SJ DeNardo 1994 Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung J Nucl Med 35 1381 1389 8046498 1:STN:280:DyaK2czit1Wjtg%3D%3D
18. M Cremonesi M Ferrari CM Grana A Vanazzi M Stabin M Bartolomei, et al. 2007 High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment J Nucl Med 48 1871 1879 17978355 10.2967/jnumed.107.044016
19. D Minarik K Sjogreen-Gleisner O Linden K Wingardh J Tennvall SE Strand, et al. 2010 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy J Nucl Med 51 1974 1978 21078799 10.2967/jnumed.110.079897
20. GA Wiseman LI Gordon PS Multani TE Witzig S Spies NL Bartlett, et al. 2002 Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial Blood 99 4336 4342 12036859 10.1182/blood.V99.12.4336 1:CAS:528:DC%2BD38XksFGlu7s%3D
21. AM Zimmer 2004 Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin) Semin Nucl Med 34 14 19 14762740 10.1053/j.semnuclmed.2003.11.001
22. G Sgouros 1993 Bone marrow dosimetry for radioimmunotherapy: theoretical considerations J Nucl Med 34 689 694 8455089 1:STN:280:DyaK3s3gtl2nuw%3D%3D
23. MG Stabin KF Eckerman WE Bolch LG Bouchet PW Patton 2002 Evolution and status of bone and marrow dose models Cancer Biother Radiopharm 17 427 433 12396706 10.1089/108497802760363213 1:STN:280:DC%2BD38njslGgtA%3D%3D
24. M Holstensson C Hindorf M Ljungberg M Partridge GD Flux 2007 Optimization of energy-window settings for scatter correction in quantitative (111)In imaging: comparison of measurements and Monte Carlo simulations Cancer Biother Radiopharm 22 136 142 17627422 10.1089/cbr.2007.307 1:CAS:528: DC%2BD2sXksF2rtrw%3D
25. A Rosset L Spadola O Ratib 2004 OsiriX: an open-source software for navigating in multidimensional DICOM images J Digit Imaging. 17 205 216 15534753 10.1007/s10278-004-1014-6
26. DR Fisher S Shen RF Meredith 2009 MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan J Nucl Med 50 644 652 19289440 10.2967/jnumed.108.057331 1:CAS:528: DC%2BD1MXltVOgt7g%3D
27. MG Stabin RB Sparks E Crowe 2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine J Nucl Med 46 1023 1027 15937315
28. C Chiesa F Botta E Di Betta A Coliva M Maccauro G Aliberti, et al. 2007 Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results Cancer Biother Radiopharm 22 113 120 17627419 10.1089/cbr.2007.302 1:CAS:528:DC%2BD2sXksF2rsbk%3D
29. S Baechler RF Hobbs HA Jacene FO Bochud RL Wahl G Sgouros 2010 Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab J Nucl Med 51 1878 1884 21098795 10.2967/jnumed.110.079947
30. C Hindorf G Glatting C Chiesa O Linden G Flux 2010 EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry Eur J Nucl Med Mol Imaging 37 1238 1250 20411259 10.1007/s00259-010-1422-4
31. D Minarik M Ljungberg P Segars KS Gleisner 2009 Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging Phys Med Biol 54 5873 5883 19759410 10.1088/0031-9155/54/19/014 1:STN:280:DC%2BD1MnktV2ktQ%3D%3D